Compare stocks

ANVS vs ZYBT

Annovis Bio, Inc. and Zhengye Biotechnology Holding Limited Class A Ordinary Shares

Compare the businesses

Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Open ANVS dashboard ↗

Zhengye Biotechnology Holding Limited Class A Ordinary Shares

Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers and local governments, as well as domestic distributors and exporting distributors. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.

Open ZYBT dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗